Maedler Kathrin, Størling Joachim, Sturis Jeppe, Zuellig Richard A, Spinas Giatgen A, Arkhammar Per O G, Mandrup-Poulsen Thomas, Donath Marc Y
Division of Endocrinology and Diabetes, Department of Medicine, University Hospital, CH-8091 Zurich, Switzerland.
Diabetes. 2004 Jul;53(7):1706-13. doi: 10.2337/diabetes.53.7.1706.
Increasing evidence indicates that a progressive decrease in the functional beta-cell mass is the hallmark of both type 1 and type 2 diabetes. The underlying causes, beta-cell apoptosis and impaired secretory function, seem to be partly mediated by macrophage production of interleukin (IL)-1beta and/or high-glucose-induced beta-cell production of IL-1beta. Treatment of type 1 and type 2 diabetic patients with the potassium channel opener diazoxide partially restores insulin secretion. Therefore, we studied the effect of diazoxide and of the novel potassium channel opener NN414, selective for the beta-cell potassium channel SUR1/Kir6.2, on glucose- and IL-1beta-induced apoptosis and impaired function in human beta-cells. Exposure of human islets for 4 days to 11.1 and 33.3 mmol/l glucose, 2 ng/ml IL-1beta, or 10 and 100 micromol/l of the sulfonylurea tolbutamide induced beta-cell apoptosis and impaired glucose-stimulated insulin secretion. The deleterious effects of glucose and IL-1beta were blocked by 200 micromol/l diazoxide as well as by 3 and 30 micromol/l NN414. By Western blotting with phosphospecific antibodies, glucose and IL-1beta were shown to activate the extracellular signal-regulated kinase (ERK) 1/2, an effect that was abrogated by 3 micromol/l NN414. Similarly, 1 micromol/l of the mitogen-activated protein kinase/ERK kinase 1/2 inhibitor PD098059 or 1 micromol/l of the l-type Ca(2+) channel blocker nimodipine prevented glucose- and IL-1beta-induced ERK activation, beta-cell apoptosis, and impaired function. Finally, islet release of IL-1beta in response to high glucose could be abrogated by nimodipine, NN414, or PD098059. Thus, in human islets, glucose- and IL-1beta-induced beta-cell secretory dysfunction and apoptosis are Ca(2+) influx and ERK dependent and can be prevented by the beta-cell selective potassium channel opener NN414.
越来越多的证据表明,功能性β细胞数量的逐渐减少是1型和2型糖尿病的共同特征。其潜在原因,即β细胞凋亡和分泌功能受损,似乎部分是由巨噬细胞产生的白细胞介素(IL)-1β和/或高糖诱导的β细胞产生的IL-1β介导的。用钾通道开放剂二氮嗪治疗1型和2型糖尿病患者可部分恢复胰岛素分泌。因此,我们研究了二氮嗪以及新型钾通道开放剂NN414(对β细胞钾通道SUR1/Kir6.2具有选择性)对葡萄糖和IL-1β诱导的人β细胞凋亡及功能受损的影响。将人胰岛暴露于11.1和33.3 mmol/l葡萄糖、2 ng/ml IL-1β或10和100 μmol/l的磺脲类药物甲苯磺丁脲4天,可诱导β细胞凋亡并损害葡萄糖刺激的胰岛素分泌。200 μmol/l的二氮嗪以及3和30 μmol/l的NN414可阻断葡萄糖和IL-1β的有害作用。通过使用磷酸特异性抗体进行蛋白质印迹分析,结果显示葡萄糖和IL-1β可激活细胞外信号调节激酶(ERK)1/2,而3 μmol/l的NN414可消除这种作用。同样,1 μmol/l的丝裂原活化蛋白激酶/ERK激酶1/2抑制剂PD098059或1 μmol/l的L型钙通道阻滞剂尼莫地平可预防葡萄糖和IL-1β诱导的ERK激活、β细胞凋亡及功能受损。最后,尼莫地平、NN414或PD098059可消除胰岛对高糖的IL-1β释放反应。因此,在人胰岛中,葡萄糖和IL-1β诱导的β细胞分泌功能障碍和凋亡依赖于钙内流和ERK,并且可被β细胞选择性钾通道开放剂NN414预防。